Januvia Tablets

Januvia (Sitagliptin Phosphate Tablets) - Product Information

Januvia (Sitagliptin Phosphate Tablets) is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Januvia has not been studied in patients with a history of pancreatitis.
We also have in stock Eltroxin Tablets (Levothyroxine Sodium Tablets) which is used to treat used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone.

Name of the Drug

Januvia Tablets.

Manufacturer of Januvia Tablets

 Merck Sharp and Dohme
Website: merck.com

Active Pharmaceutical Ingredient

The active ingredient present in Januvia tablets is Sitagliptin Phosphate. Each 50 mg tablet contains Sitagliptin Phosphate monohydrate, equivalent to 50 mg Sitagliptin. Each 100 mg tablet contains Sitagliptin Phosphate monohydrate, equivalent to 100 mg Sitagliptin.

Uses of Januvia Tablets

Januvia Tablets is used to treat adult patients with type 2 diabetes mellitus. Januvia is indicated to improve glycaemic control:
As monotherapy:
In patients inadequately controlled by diet and exercise alone and for whom Metformin is inappropriate due to contraindications or intolerance.
as dual oral therapy in combination with:
Metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
A sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
Januvia is also indicated as add-on to insulin (with or without Metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Januvia (Sitagliptin Phosphate Tablets) - Dosage

Sitagliptin Phosphate tablets should be administered exactly as suggested by your doctor. Your doctor may recommend a dosage of Januvia tablets depending on your age, medical requirement, body weight, other medical conditions, and current medications.
The recommended dose of Januvia (Sitagliptin Phosphate Tablets) is 100 mg once daily. Januvia can be taken with or without food. Dosage adjustment is recommended for patients with moderate or severe renal insufficiency or end-stage renal disease.
Januvia tablets work effectively if the amount of Sitagliptin is maintained at a constant level in the body. You should be systematic about the daily schedule for the medication such that you take tablets at about the same time every day, to get the maximum benefit of the medication. Continue taking Januvia tablets without missing any doses for the recommended treatment period and do not stop the treatment suddenly even if you feel better.

Please consult your doctor for exact dosing instructions. Januvia tablets (Sitagliptin Phosphate tablets) should be administered in the dose prescribed by the doctor and for the duration recommended by the doctor.

Missed Dose

If you forget to take your regular Januvia tablets dose on time, take it whenever you remember.
If you remember the next day, skip the missed dose and take your scheduled dose. Do not take a double dose to compensate the missed dose.

Sitagliptin Phosphate Tablets Mechanism of Action – How Does Januvia Work?

Sitagliptin's mechanism of action involves inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, which breaks down incretin hormones (like GLP-1 and GIP) in the body.
By prolonging the active life of incretins, sitagliptin increases their levels. This leads to glucose-dependent insulin secretion by the pancreas and suppression of glucagon release, which together reduce glucose levels in the blood and improve glycemic control in patients with type 2 diabetes.

Storage Instructions for Januvia (Sitagliptin Phosphate Tablets)

Store Januvia tablets at controlled room temperature (20°C to 25°C),protected from heat, moisture, and sunlight. Excursions are permitted from 15°C to 30°C.
Retain the original packing of the medication and do not consume Januvia tablets past its expiration date printed on the blister pack. Keep the pack of Januvia tablets away from the reach of children and pets. Do not dispose Januvia tablets(Sitagliptin Phosphate tablets) along with domestic waste or sewage. Consult your doctor or pharmacist about the correct method of disposal.

Contraindications

Januvia tablets are contraindicated in patients with a hypersensitivity to Sitagliptin Phosphate (such as anaphylaxis or angioedema) or any inactive ingredient present in tablets.

Overdose

Talk to your doctor if you take more than your prescribed dose of Sitagliptin and have stomach pains. are feeling or being sick (nausea or vomiting) feel dizzy.
In the event of an overdose, it is reasonable to employ supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy as dictated by the patient's clinical status.
Sitagliptin is modestly dialyzable. In clinical studies, approximately 13.5% of the dose was removed over a 3- to 4-hour hemodialysis session. Prolonged hemodialysis may be considered if clinically appropriate. It is not known if sitagliptin is dialyzable by peritoneal dialysis.

Warnings and Precautions

Acute Pancreatitis:
There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue Januvia.
Acute Renal Failure:
There have been postmarketing reports of acute renal failure, sometimes requiring dialysis. Dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with ESRD. Assessment of renal function is recommended prior to initiating Januvia and periodically thereafter.
Risk Of Hypoglycemia:
There is an increased risk of hypoglycemia when Januvia is added to an insulin secretagogue (e.g., sulfonylurea) or insulin therapy. Consider lowering the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia.
Hypersensitivity Reactions:
There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with Januvia such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. In such cases, promptly stop Januvia , assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes.
Macrovascular Risk Reduction:
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Januvia or any other anti-diabetic drug.
Heart Failure:
An association between dipeptidyl peptidase-4 (DPP-4) inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class.
Severe and Disabling Arthralgia:
There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication.

Side Effects of Januvia (Sitagliptin Phosphate Tablets)

Side effects reported in 5% or more of patients treated with Januvia and more commonly than in patients treated with placebo are: upper respiratory tract infection, nasopharyngitis and headache. In the addon to sulfonylurea and add-on to insulin studies, hypoglycemia was also more commonly reported in patients treated with Januvia compared to placebo.

Sitagliptin Phosphate (Januvia Tablets) During Pregnancy

Januvia (Sitagliptin Phosphate tablets) has been classified by the US FDA as Pregnancy Category B.
The limited available data with Januvia in pregnant women are not sufficient to inform a drug associated risk for major birth defects and miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy. No adverse developmental effects were observed when Sitagliptin was administered to pregnant rats and rabbits during organogenesis at oral doses up to 30-times and 20-times, respectively, the 100 mg clinical dose, based on AUC.
Do not use this medicine without your doctor's consent in case you are pregnant. Stop using this medication and inform your doctor immediately if you become pregnant during treatment.

Nursing Considerations

There is no information regarding the presence of Januvia (Sitagliptin Phosphate tablets) in human milk, the effects on the breastfed infant, or the effects on milk production. Sitagliptin is present in rat milk and therefore possibly present in human milk.
Do not use this medication without telling your doctor if you are breast-feeding a baby.

Buy Sitagliptin 50 mg and 100 mg Pills Online From Only $1.56 per Pill

You can buy Sitagliptin Phosphate tablets online from Everest Online Pharmacy at a cheap price. Januvia 50 mg and 100 mg pills, manufactured by manufactured by Merck Sharp and Dohme, India are supplied in a blister strip of 7 tablets. The 50 mg tablets cost only $1.56 per unit when you place an order for 140 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith. It is without a warrant of any kind, expressed or implied.

Shipping Restriction